Yahoo Web Search

Search results

1. • Dear Doctor: Can I use over-the-counter eye drops while on medications for macular degeneration?

     OregonLive.com· 8 hours ago

     ROACH: I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). Is it safe to use over-the-counter ...

2. • Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients

     WKBN 27 Youngstown· 2 days ago

     The study enrolled patients with newly diagnosed wet AMD and active choroidal neovascularization (CNV), where anti-VEGF therapy was indicated.

3. • 

     2 Small-Cap Growth Stocks With Room to Run

     Motley Fool via Yahoo Finance· 1 day ago

     Currently, Wall Street analysts believe the company's shares could be undervalued by as much as 210%. The reason? Ocular is developing a novel therapy...

4. • Ocugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan Capital

     ETF DAILY NEWS· 4 days ago

     Ocugen (NASDAQ:OCGN – Get Free Report) had its price objective increased by stock analysts at Chardan Capital from $4.00 to $5.00 in a research report issued on Monday, Benzinga reports. Chardan ...

5. • 

     Health Care Roundup: Market Talk

     The Wall Street Journal· 3 days ago

     Moreover, its planned launch of aflibercept—for patients living with wet macular degeneration—could be a potentially significant biosimilar ...

6. • REGENXBIO (NASDAQ:RGNX) Stock Price Down 3.1% Following Insider Selling

     ETF DAILY NEWS· 7 days ago

     REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report)’s share price was down 3.1% on Thursday after an insider sold shares in the company. The company traded as low as $16.21 and last traded at $16.50 ...

7. • PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC...

     Morningstar· 3 days ago

     Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public

8. • 

     Local women with low vision gather to share experiences, advances in tech

     telegraphherald.com· 5 days ago

     Gathered around a long table in the back of Caroline’s Restaurant in Dubuque, a group of women...

9. • UBS Group Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,099.00

     ETF DAILY NEWS· 6 days ago

     Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price raised by UBS Group from $1,090.00 to $1,099.00 in a research note published on Wednesday, Benzinga reports. The brokerage ...

10. • StockNews.com Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

      ETF DAILY NEWS· 4 days ago

      Several other research analysts have also weighed in on REGN. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research ...